Lung cancer surgery: innovations and future perspectives
Open Access
- 2 January 2024
- journal article
- review article
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 3 (1) , 1-9
Abstract
Nine decades ago in 1933, Evarts A. Graham performed the first successful pneumonectomy in a patient with primary pulmonary squamous cell carcinoma. The patient survived for another 30 years, which drew the curtain on the surgical treatment of lung cancer. Surgical resection continues to be the cornerstone of multidisciplinary treatment for patients with early-stage non-small cell lung cancer and a proportion of those with locally advanced disease. Moreover, recent years have seen developments in automatic control, biomechanics, robotics, image transmission, artificial intelligence, three-dimensional reconstruction and printing, biological pharmacy, and molecular biology. Therefore, there is now an increasing focus on how to integrate these technologies into lung cancer surgery to improve quality of life, resect the tumor accurately, expand the population that is suitable for surgical management, predict disease recurrence with better accuracy, and ultimately achieve long-term survival. This article systematically reviews the innovative achievements that may be detrimental to current clinical practice and in future clinical trials, and simultaneously provides a brief overview of the polyvagal perspective in this field.Keywords
Funding Information
- the Shenzhen Key Medical Discipline Construction Fund (SZXK075)
- Sanming Project of Medicine in Shenzen Municipality (SZSM201612097)
- National Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen (E010322008)
This publication has 26 references indexed in Scilit:
- A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2022
- Prognostic impact of a ground-glass opacity component in clinical stage IA non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2021
- Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant TherapyCancers, 2020
- Driving the Improvement of Lung Cancer PrognosisCancer Cell, 2020
- The Epidemiology of Ground Glass Opacity Lung Adenocarcinoma: A Network-Based Cumulative Meta-AnalysisFrontiers in Oncology, 2020
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryAnnals of Oncology, 2019
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialThe Lancet Respiratory Medicine, 2019
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerNew England Journal of Medicine, 2018
- Near-infrared dye marking for thoracoscopic resection of small-sized pulmonary nodules: comparison of percutaneous and bronchoscopic injection techniquesJournal of Cardiothoracic Surgery, 2018
- New clinically applicable method for visualizing adjacent lung segments using an infrared thoracoscopy systemThe Journal of Thoracic and Cardiovascular Surgery, 2010